Safety and Efficacy of Once-Daily Oral Paltusotine in Acromegaly: ACROBAT Advance Open-Label Extension Up to 4 Years
Clicks: 1
ID: 318927
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #352 of 362 articles by views in the journal of clinical endocrinology & metabolism
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 362 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
CONTEXT: Paltusotine is the first non-peptide selective somatostatin 2 receptor agonist approved as once-daily oral treatment for acromegaly. OBJECTIVE: To evaluate long-term treatment with paltusotine in patients with acromegaly previously on an injected somatostatin receptor ligand (SRL)-based regimen. METHODS: ACROBAT Advance is an ongoing open-label extension (OLE) study. Interim results (up to year 4) are reported. Enrolled patients had completed a phase 2 parent study: ACROBAT Edge (baseline insulin-like growth factor I [IGF-I] > 1× upper limit of normal [ULN] on injected octreotide or lanreotide ± cabergoline, or baseline IGF-I ≤ 1×ULN with combination therapy or pasireotide) or ACROBAT Evolve (baseline IGF-I ≤ 1×ULN on injected SRL monotherapy). Maximum paltusotine dose was initially 40 mg, then 60 mg, when a tablet formulation became available in year 3. Adjunctive treatment with cabergoline or pegvisomant was allowed as clinically indicated. RESULTS: Forty-three patients (88% of eligible patients from ACROBAT Edge and Evolve) enrolled in the OLE. Median (interquartile range) IGF-I levels were: 1.15×ULN (0.84, 1.46) at parent study baseline (n = 43), 1.17×ULN (0.98, 1.54) at Advance week 3 (n = 43), and 1.01×ULN (0.83, 1.13) at Advance week 207 (n = 20). Growth hormone levels, acromegaly symptoms, and pituitary tumor size remained stable. Paltusotine was well tolerated, with no unexpected safety findings observed. As of this analysis, 8 (18.6%) patients had discontinued from the study, including 2 (4.7%) due to adverse events. CONCLUSIONS: Once-daily oral paltusotine treatment was well tolerated and resulted in long-term disease control, including biochemical, symptom, and pituitary tumor stability, for up to 4 years.
| Reference Key |
openalex_W7166202985
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Mônica R. Gadelha, Murray B. Gordon, Mirjana Doknić, Emese Mezősi, M Tóth, Hapal Randeva, César Luiz Boguszewski, Christopher Davidson, Alessandra Casagrande, Theresa Jochelson, Alan Krasner |
| Journal | the journal of clinical endocrinology & metabolism |
| Year | 2026 |
| DOI |
10.1210/clinem/dgag254
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.